| 引用本文:何宜航1，杨桂燕1，阳向波2，邹俊波1，纪奇森2，张帅杰3，杨明2,4.熟三七对Lewis肺癌的抑制及对联合用药的增效减毒作用研究[J].世界中医药,2015,10(05):. |
|
| 熟三七对Lewis肺癌的抑制及对联合用药的增效减毒作用研究 |
| Inhibition effect of steamed Panax notoginseng on Lewis lung cancer and the “effect-enhancing and toxicity-reducing effect” when use in combination with chemotherapy drugs |
| 投稿时间：2015-04-07 |
| DOI：10.3969/j.issn.1673-7202.2015.05.008 |
| 中文关键词: 熟三七 Lewis肺癌 抑制 联合用药 增效减毒 |
| English Keywords:Steamed Panax notoginseng Lewis lung cancer Tumor inhibition Combination Effect-enhancing and toxicity-reducing effect |
| 基金项目: |
|
| 摘要点击次数: 1359 |
| 全文下载次数: 1531 |
| 中文摘要: |
| 目的：考察熟三七粉对Lewis肺癌的抑制作用及与紫杉醇、培美曲塞二钠联合用药的增效减毒作用。方法：首先将接种Lewis肺癌的C57BL/6小鼠按体重随机分为模型组，阳性组，生、熟三七低、中、高剂量组，每组13~14只。其中生、熟三七粉按低、中、高剂量（585 mg·kg-1,1170 mg·kg-1,2340 mg·kg-1）连续灌胃15 d，阳性组以60 mg·kg-1剂量于第1天腹腔注射CTX 1次，试验结束后计算抑瘤率，并统计给药前后体重、体重比值（FBW/IBW）、死亡情况；再将新接种Lewis肺癌的C57BL/6小鼠按体重随机分为9组,每组10只，即模型组（0.5% CMC-Na溶液）、熟三七组、生三七组、紫杉醇组、熟三七联合紫杉醇组、生三七联合紫杉醇组、ALIMTA组、熟三七联合ALIMTA组、生三七联合ALIMTA组。生、熟三七以1170 mg·kg-1连续灌胃给药15 d，紫杉醇（10 mg·kg-1）、ALIMTA（120.3 mg·kg-1）自给药第1天起每3 d腹腔注射1次，共3次。试验结束后计算抑瘤率，测定外周血象，并考察给药前后体重、体重比值（FBW/IBW）、死亡情况。结果：与模型组相比，熟三七（1170 mg·kg-1）具有极显著抑瘤率41%（P<0.01）、生三七（2340 mg·kg-1）具有显著抑瘤率（P<0.05），但无临床意义，且表现出一定不良反应；生、熟三七与紫杉醇、ALIMTA连用均能提高抑瘤率，且熟三七表现出降低紫杉醇毒副作用的趋势，而生三七却表现出一定不良反应。结论：熟三七能显著抑制Lewis肺癌生长，与化药联合使用可表现出较好协同作业用，并可拮抗紫杉醇毒副作用；生三七对肿瘤生长的抑制不具有临床意义，虽在联合用药中表现出较好的协同作用，但不良反应明显。 |
| English Summary: |
| To Investigate the inhibition effect of steamed Panax notoginseng on Lewis lung cancer, and find out whether there is a effect-enhancing and toxicity-reducing effect when use in combination with paclitaxel or pemetrexed disodium. Methods: C57BL/6 mice inoculated with Lewis lung cancer were randomly divided into model group, positive group, raw Panax notoginseng low, medium and high dose group, steamed Panax notoginseng low, medium and high dose group(each group n=13～14). Among them, raw and steamed Panax notoginseng groups received intragastric administration according to low, middle, high dose(585 mg·kg-1, 1170 mg·kg-1, 2340 mg·kg-1), positive group mice received intraperitoneal injection of CTX(60 mg·kg-1) on the first day. After the trial, calculated inhibition rate against tumor and recorded body weight before/after administration, body weight ratio(FBW/IBW) and death. Then the new Lewis lung cancer inoculated C57BL/6 mice were randomly divided into 9 groups (n=10), model group (0.5% CMC-Na solution), steamed Panax notoginseng group, raw Panax notoginseng group, paclitaxel group, steamed Panax notoginseng plus paclitaxel group, raw Panax notoginseng plus paclitaxel group, ALIMTA group, steamed Panax notoginseng plus ALIMTA group and raw Panax notoginseng plus ALIMTA group. Steamed and raw Panax notoginseng were continuously intragastric administrated at the dose of 1170 mg·kg-1, and paclitaxel(15 d, 10 mg·kg-1), ALIMTA (120.3 mg·kg-1) were intraperitoneal injected since Day 1(every three days, 3 times in total). After the trial, calculated inhibition rate against tumor, determined peripheral hemogram and recorded body weight before/after administration, body weight ratio(FBW/IBW) and death. Results: Compared with the model group, steamed Panax notoginseng(1170 mg·kg-1) showed significantl inhibition rate(41%, P<0.01); raw Panax notoginseng(2340 mg·kg-1) also showed significantl inhibition rate(P<0.05), but with no clinical significance, and had several adverse reactions. Steamed and raw Panax notoginseng improved the inhibition rate of paclitaxel and ALIMTA; Steamed Panax notoginseng seemed to reduce the toxicity of paclitaxel, whereas raw Panax notoginseng increased the toxicity of chemotherapy drugs. Conclusion: Steamed Panax notoginseng significantly inhibit the growth of Lewis lung cancer; and when use in combination with chemotherapy drugs, could improve the inhibition rate, meanwhile, reduce the toxicity of chemotherapy drugs. There is no clinical significance of antitumor effect of raw Panax notoginseng; although raw Panax notoginseng could also improve the inhibition rate of chemotherapy drugs, but exhibit obvious adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
